Skip to main content
Kymera Therapeutics, Inc. logo

Kymera Therapeutics, Inc. — Investor Relations & Filings

Ticker · KYMR ISIN · US5015751044 US Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 528 across all filing types
Latest filing 2026-06-08 Board/Management Inform…
Country US United States of America
Listing US KYMR

About Kymera Therapeutics, Inc.

https://www.kymeratx.com/

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering the field of targeted protein degradation (TPD) to develop novel small molecule medicines. The company's proprietary drug discovery engine, Pegasus™, enables the creation of first-in-class therapeutics designed to selectively degrade disease-causing proteins, thereby addressing the root cause of illness. Kymera's pipeline is focused on developing oral medicines for diseases with high unmet medical needs, particularly in the areas of immunology, inflammation, and oncology. The company aims to redefine treatment paradigms by targeting proteins that have been previously considered undruggable.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 92% confidence The document is a Form 8-K current report with Item 5.02 reporting the resignation (departure) of the Chief Operating Officer and his continued advisory role. This is a management change announcement. According to the classification definitions, changes in senior management belong to Board/Management Information (MANG).
2026-06-08 English
10-Q - Kymera Therapeutics, Inc. (0001815442) (Filer)
Interim / Quarterly Report Q1 2026
2026-04-30 English
8-K - Kymera Therapeutics, Inc. (0001815442) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 30, 2026, reporting the financial results for the quarter ended March 31, 2026. It specifically states that a press release with the financial results is furnished as an exhibit. The document itself is a current report announcing quarterly financial results, which aligns with an Earnings Release. The length is 3512 characters, which is short and typical for an 8-K earnings release announcement. It is not the full quarterly report or detailed financial statements, but an initial announcement of quarterly results. Therefore, the appropriate classification is Earnings Release (ER).
2026-04-30 English
8-K - Kymera Therapeutics, Inc. (0001815442) (Filer)
Board/Management Information Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated March 25, 2026. It reports an amendment to the company's bylaws regarding the designation of federal district courts as the exclusive forum for certain securities-related complaints. The document includes a description of the bylaw amendment and references an exhibit containing the full text of the amendment. There are no financial statements, earnings data, or detailed management discussion. The content focuses on a governance change (amendment to bylaws) approved by the Board of Directors. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or governance documents. The document length is 3861 characters, which is relatively short but contains substantive information about a governance change rather than just an announcement of a report publication. Therefore, the appropriate classification is MANG with high confidence.
2026-03-27 English
SCHEDULE 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)
Major Shareholding Notification
2026-03-27 English
4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
Director's Dealing
2026-03-25 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.